BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fock K, Teo E, Ang T, Chua T, Ng T, Tan Y. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia. World J Gastroenterol 2005; 11(20): 3091-3098 [PMID: 15918196 DOI: 10.3748/wjg.v11.i20.3091] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747-757, e350. [PMID: 22309489 DOI: 10.1111/j.1365-2982.2012.01888.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 8.8] [Reference Citation Analysis]
2 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
3 Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, Holtmann G, Nandurkar S. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23:8-22. [PMID: 18171339 DOI: 10.1111/j.1440-1746.2007.05249.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 8.1] [Reference Citation Analysis]
4 Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213-224. [PMID: 21083596 DOI: 10.1111/j.1365-2036.2010.04508.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Umemura K, Furuta T. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 2011; 17(14): 1858-1865 [PMID: 21528060 DOI: 10.3748/wjg.v17.i14.1858] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
6 DeVault KR. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther. 2006;23 Suppl 1:33-39. [PMID: 16483268 DOI: 10.1111/j.1365-2036.2006.02798.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
7 Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26:69-77. [PMID: 17555423 DOI: 10.1111/j.1365-2036.2007.03350.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 3.8] [Reference Citation Analysis]
8 Dadabhai A, Friedenberg FK. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf 2009;8:119-26. [PMID: 19236223 DOI: 10.1517/14740330802622892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
9 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, Ai MH, Wang J, Lv XG, Yang ZR, Dong WG. Proton pump inhibitor for non-erosive reflux disease: A meta-analysis. World J Gastroenterol 2013; 19(45): 8408-8419 [PMID: 24363534 DOI: 10.3748/wjg.v19.i45.8408] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
11 Kagami T, Sugimoto M, Ichikawa H, Sahara S, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19. Eur J Clin Pharmacol 2015;71:1467-75. [PMID: 26427705 DOI: 10.1007/s00228-015-1941-9] [Reference Citation Analysis]
12 Sun J, Yuan YZ, Hou XH, Zou DW, Lu B, Chen MH, Liu F, Wu KC, Zou XP, Li YQ, Zhou LY. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis. World J Gastroenterol 2015; 21(22): 6965-6973 [PMID: 26078574 DOI: 10.3748/wjg.v21.i22.6965] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. Aliment Pharmacol Ther 2006;24:1445-51. [PMID: 17032285 DOI: 10.1111/j.1365-2036.2006.03140.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
14 Hiyama T, Matsuo K, Urabe Y, Fukuhara T, Tanaka S, Yoshihara M, Haruma K, Chayama K. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux disease. J Gastroenterol Hepatol. 2009;24:1326-1332. [PMID: 19702900 DOI: 10.1111/j.1440-1746.2009.05879.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
15 Vachhani R, Olds G, Velanovich V. Esomeprazole: a proton pump inhibitor. Expert Review of Gastroenterology & Hepatology 2014;3:15-27. [DOI: 10.1586/17474124.3.1.15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
16 Nagahara A, Suzuki T, Nagata N, Sugai N, Takeuchi Y, Sakurai K, Miyamoto M, Inoue K, Akiyama J, Mabe K. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis. J Gastroenterol. 2014;49:1536-1547. [PMID: 24366288 DOI: 10.1007/s00535-013-0925-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
17 Kusano M, Shirai N, Yamaguchi K, Hongo M, Chiba T, Kinoshita Y; The Acid-Related Symptom (ARS) Research Group. It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients. Dig Dis Sci 2008;53:3082-94. [DOI: 10.1007/s10620-008-0290-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
18 Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009;5:1113-1124. [PMID: 19606942 DOI: 10.1517/17425250903124363] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
19 Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G; ON BEHALF OF THE TREAT STUDY GROUP. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care - prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Alimentary Pharmacology & Therapeutics 2009;29:967-78. [DOI: 10.1111/j.1365-2036.2009.03948.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
20 Craven MR, Kia L, O'Dwyer LC, Stern E, Taft TH, Keefer L. Systematic review: methodological flaws in racial/ethnic reporting for gastroesophageal reflux disease. Dis Esophagus 2018;31. [PMID: 29444213 DOI: 10.1093/dote/dox154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Ashida K, Kinoshita Y, Hongo M; The Japan Rabeprazole Study Group for NERD. Acid-Suppressive Effect of Rabeprazole 5 mg and 10 mg Once Daily by 24-Hour Esophageal pH Monitoring in Patients with Non-erosive Reflux Disease in Japan: A Multicenter, Randomized, Parallel-Group, Double-Blind Pharmacodynamic Study. Dig Dis Sci 2011;56:2333-42. [DOI: 10.1007/s10620-011-1583-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Moraes-filho JPP, Navarro-rodriguez T, Barbuti R, Eisig J, Chinzon D, Bernardo W. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus. Arq Gastroenterol 2010;47:99-115. [DOI: 10.1590/s0004-28032010000100017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol. 2012;5:49-59. [PMID: 22649281 DOI: 10.2147/ceg.s23926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
24 Nagahara A, Miwa H, Asaoka D, Shimada Y, Sasaki H, Matsumoto K, Osada T, Hojo M, Watanabe S. Pretreatment prediction of symptom response to proton pump inhibitor therapy. J Gastroenterol Hepatol 2015;30 Suppl 1:25-30. [PMID: 25827800 DOI: 10.1111/jgh.12744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
26 Lee ES, Kim N, Lee SH, Park YS, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009;30:154-164. [PMID: 19392871 DOI: 10.1111/j.1365-2036.2009.04021.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
27 Tan VP, Wong WM, Cheung TK, Lai KC, Hung IF, Chan P, Pang R, Wong BC. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. J Gastroenterol 2011;46:906-12. [PMID: 21538030 DOI: 10.1007/s00535-011-0402-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
28 Seo KA, Lee SJ, Kim KB, Bae SK, Liu KH, Kim DH, Shin JG. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42:278-284. [PMID: 22022918 DOI: 10.1517/13543776.2013.741121] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
29 Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment Pharmacol Ther Symp Series 2006;2:340-50. [DOI: 10.1111/j.1746-6342.2006.00065.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
30 Maiti R, Jaida J, Israel PL, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother 2011;2:150-7. [PMID: 21897706 DOI: 10.4103/0976-500X.83278] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther. 2013;38:1129-1137. [PMID: 24099474 DOI: 10.1111/apt.12492] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
32 Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47:1-6. [PMID: 18076214 DOI: 10.2165/00003088-200847010-00001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]